In an article published in April 2022 in Gut , the authors introduced an enhancer-based classification system known as EpiC, which facilitated the epigenomic categorisation of colorectal cancer (CRC).1 Following this, a novel approach was presented in a recent issue of Nature Genetics , dated 13 February, by Malla et al . This study diverges from traditional gene-centric analysis typically seen in transcriptomics-based classification by incorporating pathway analysis and gene ontology.2 The EpiC study posited that tumours from consensus molecular subtype 1 (CMS1) and CMS4 samples, which include those enriched in metabolic and stem cell characteristics, could be categorised into EpiC1 and EpiC2, respectively.3 The study’s enhancer-based approach effectively segregates the CMS2 subtype into two distinct EpiC clusters; EpiC3 and EpiC4 with significantly different survival rates (figure 1). This finding underscores the potential of enhancer-based epigenomic subtyping in offering a better understanding of CRC, which could lead to more efficacious …

中文翻译：

---

超越传统亚型：结直肠癌的多层次基因组视角


在 2022 年 4 月发表在 Gut 上的一篇文章中，作者介绍了一种基于增强子的分类系统，称为 EpiC，该系统促进了结直肠癌 （CRC） 的表观基因组分类。在此之后，Malla 等人在 2 月 13 日的最新一期《自然遗传学》上提出了一种新方法。这项研究通过结合通路分析和基因本体论，与基于转录组学的分类中常见的传统以基因为中心的分析不同。2 EpiC 研究假设来自共有分子亚型 1 （CMS1） 和 CMS4 样本的肿瘤，包括富含代谢和干细胞特征的肿瘤，可以分别分为 EpiC1 和 EpiC2.3 该研究基于增强子的方法有效地将 CMS2 亚型分离为两个不同的 EpiC集群;EpiC3 和 EpiC4 的存活率显著不同（图 1）。这一发现强调了基于增强子的表观基因组亚型在更好地了解 CRC 方面的潜力，这可能会导致更有效的 ...